Panitumumab-IRDye800 during head and neck surgery
Treatments studied
Part of Cancer clinical trials.
This Phase 2 study tests a targeted medicine (panitumumab-IRDye800) given around the time of surgery for head and neck squamous cell cancer. It aims to improve doctors’ ability to find and remove cancer tissue during planned surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have biopsy-proven squamous cell cancer in the head and neck area
- You’re scheduled for curative-intent surgery (recurrent or a new primary is allowed)
- You’re 18 or older, and your expected survival is more than 12 weeks
- Your overall health/activity is good enough (Karnofsky at least 70% or ECOG 0–1)
- Your blood and organ tests are within required safety ranges (blood counts, kidney, liver)
- You haven’t had an investigational drug in the last 30 days before the first dose
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a combination of a targeted antibody (panitumumab) and a special dye can help surgeons see cancer cells more clearly during surgery. It may help ensure that all cancer is removed.
This early-phase study compares a special imaging marker with a standard PET scan to help identify head and neck squamous cell carcinoma before surgery. It may help doctors see where cancer is (especially if lymph nodes look negative) so surgery planning can be more accurate.
This trial tests a special fluorescent dye attached to panitumumab, a cancer-targeting antibody, to help surgeons see tumor tissue more clearly during head and neck cancer surgery. The goal is to improve removal of all cancer cells while sparing healthy tissue.
This early-stage study tests two different imaging (scanning) methods to better detect head and neck cancer. Your results from the scans may help doctors see where disease is before standard surgery to remove lymph nodes in the neck.
This trial tests a special dye drug (panitumumab-IRDye800) that may help surgeons better see lung cancer areas while operating. If it works, it could improve how well cancer tissue is found and removed during planned lung surgery.
This trial tests whether a targeted antibody with a fluorescent dye can help surgeons see and remove pancreatic cancer during planned surgery. It’s an early-phase study, so the main goal is to see if the approach is safe and useful around the time of the operation.
Hear when a new Head and Neck Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.